Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study-Reference-Cited by-同舟云学术

Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study

Published:2005-02 Issue:2 Volume:23 Page:445-453
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:Journal of Hypertension

Author:

Hasebe Naoyuki,Kikuchi Kenjiro

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Reference51 articles.

1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 Report

2. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

3. 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*

4. Guidelines for the Management of Hypertension for General Practitioners.

5. Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension?

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study;Frontiers in Pharmacology;2022-03-09

2. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta‐analysis;The Journal of Clinical Hypertension;2022-03-02

3. Data mining methodology for response to hypertension symptomology-application to COVID-19-related pharmacovigilance;ELIFE;2021

4. Data mining methodology for response to hypertension symptomology—application to COVID-19-related pharmacovigilance;eLife;2021-11-23

5. Data-driven methodology for discovery and response to pulmonary symptomology in hypertension through AI and machine learning: Application to COVID-19 related pharmacovigilance;2021-06-12